Pharmacovigilance is the system for watching a medication's safety after it is approved. Clinical trials enroll a few thousand carefully selected people for a limited time, so rare, delayed, or population-specific side effects only surface once millions of people are taking a drug. Regulators (the FDA, the European Medicines Agency), manufacturers, and academic researchers collect adverse-event reports, compare them against expected rates, and decide whether a label change, warning, or further study is needed.
Many GLP-1 safety questions — suicidal ideation, gastroparesis, hair loss, a rare eye condition (NAION) — have been raised or investigated this way. One common tool is the "reporting odds ratio," which compares how often a side effect is reported with one drug versus all other drugs in the database; a high ratio flags a signal worth investigating but, because reporting is voluntary and uneven, does not by itself show the drug caused the effect. Follow-up usually means large cohort studies or trial re-analyses, which is how the 2024 EMA review concluded the available evidence did not support a causal link between GLP-1s and suicidal thoughts. See mood changes and anhedonia on a GLP-1.